Lu AF87908 is an anti-tau monoclonal antibody developed by Lundbeck for the treatment of Alzheimer's disease and other tauopathies[1]. It represents Lundbeck's entry into the tau immunotherapy field.
Lu AF87908 targets tau protein for therapeutic intervention[1:1]:
First-in-human studies are evaluating the safety, tolerability, and pharmacokinetics of Lu AF87908[1:2].
Lu AF87908 is in active Phase 1 clinical development by Lundbeck. The program represents an important addition to the tau immunotherapy pipeline.